Mode
Text Size
Log in / Sign up

Earlier endovascular therapy within 24 hours associated with smaller infarct and better outcomes in LVO strokeDoes waiting longer for stroke treatment cause more brain damage and worse recovery?

AI-generated summary of the cited source, checked by automated accuracy review. How we work

Key Takeaway
Note that earlier EVT within 24h associates with smaller infarct and better outcomes in LVO stroke.

This single-center prospective cohort study included 216 patients with anterior circulation large-vessel occlusion stroke who underwent endovascular therapy within 24 hours of symptom onset. The population was stratified into three groups based on onset-to-groin time: 0–6 hours, 6–12 hours, and 12–24 hours. The primary analysis compared outcomes across these time-stratified groups, while secondary outcomes included reperfusion quality, final infarct volume, infarct progression, NIHSS change, 90-day modified Rankin Scale, and serial inflammatory biomarkers measured up to 72 hours.

The main results demonstrated a clear stepwise decline in outcomes with treatment delay. Final infarct volume was 38.7 mL in the 0–6 hour group, increasing to 51.3 mL in the 6–12 hour group and 64.5 mL in the 12–24 hour group. Functional independence, defined as a modified Rankin Scale score of 0 to 2 at 90 days, occurred in 64.9% of the 0–6 hour group, compared with 50.0% in the 6–12 hour group and 35.7% in the 12–24 hour group. Reperfusion quality, assessed by mTICI 2b–3 rates and first-pass effect, was higher with earlier intervention.

Patients treated within the first 6 hours exhibited blunted peaks and faster resolution of inflammatory biomarkers, including IL-6, MMP-9, C-reactive protein, and the neutrophil-to-lymphocyte ratio. Safety data indicated that symptomatic intracranial hemorrhage, procedural complications, and in-hospital mortality were low and comparable across all three time strata. However, the study was limited by its observational design, which precludes causal inference. These results suggest that earlier endovascular therapy within the 24-hour window is associated with reduced tissue injury and improved clinical outcomes, but further research is needed to confirm these associations.

Imagine having a major blockage in the artery feeding your brain. Every minute counts, but what happens if you wait? This study looked at 216 patients who had a large blockage in the front part of their brain circulation. They all received a procedure to clear the blockage within 24 hours. The researchers watched how their brains healed and how they felt after 90 days.

The results were stark. Patients treated within the first six hours had the smallest amount of dead brain tissue. Those treated between six and 12 hours had more damage, and those treated between 12 and 24 hours had the most. This pattern held true for how well blood flow was restored and how quickly inflammation markers in the blood went down. Inflammation is the body's reaction to injury, and earlier treatment kept it under control.

By 90 days, the difference in recovery was clear. About 65% of the early group could live independently, but only about 36% of the late group could do the same. The study also tracked safety and found that serious complications like bleeding or death were low and similar across all groups. However, because this was an observational study, we see associations, not proof that the delay directly caused the harm. Still, the message for patients is urgent: getting treated as fast as possible offers the best shot at a full recovery.

What this means for you:
Earlier stroke treatment within 24 hours is linked to less brain damage and better recovery.

Study Details

Study typeCohort
EvidenceLevel 3
PublishedMar 2026
View Original Abstract ↓
BackgroundThe impact of endovascular therapy (EVT) timing within the 24-h window on tissue injury and post-ischemic inflammation in large-vessel occlusion stroke remains uncertain.MethodsIn a single-center prospective cohort, 216 anterior circulation large-vessel occlusion patients treated with EVT ≤ 24 h were stratified by onset-to-groin time: 0–6 h (n = 74), 6–12 h (n = 72), and 12–24 h (n = 70). Serial IL-6, TNF-α, IL-1β, MMP-9, C-reactive protein, and neutrophil-to-lymphocyte ratio were measured to 72 h; reperfusion quality, final infarct volume, infarct progression, NIHSS change, and 90-day modified Rankin Scale (mRS) were compared.ResultsBaseline demographics, risk factors, stroke severity, and inflammatory profiles were similar across groups. Earlier EVT yielded higher mTICI 2b–3 rates and more first-pass effect, with fewer device passes and shorter procedures. Final infarct volume increased stepwise with delay (38.7, 51.3, and 64.5 mL in the 0–6 h, 6–12 h, and 12–24 h groups), paralleled by greater infarct progression. NIHSS improvement at 24 h and day 7 was greatest in the 0–6 h group, and functional independence at 90 days declined with later treatment (mRS 0–2: 64.9% vs 50.0% vs 35.7%). Symptomatic intracranial hemorrhage, procedural complications, and in-hospital mortality were low and comparable. Patients treated within 0–6 h showed blunted peaks and faster resolution of IL-6, MMP-9, C-reactive protein, and neutrophil-to-lymphocyte ratio, consistent with a more favorable neuroinflammatory trajectory. These associations remained consistent in adjusted and sensitivity analyses.ConclusionWithin 24 h, earlier EVT was associated with more favorable reperfusion metrics, smaller infarct burden, lower circulating inflammatory biomarkers, and better 90-day functional outcome, without an apparent increase in major safety events. Given the observational design, these findings should be interpreted as associations rather than causal effects.
Free Newsletter

Clinical research that matters. Delivered to your inbox.

Join thousands of clinicians and researchers. No spam, unsubscribe anytime.